Krystal Biotech, Inc. (KRYS) - Stock Analysis
Last updated: Mar 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Selected as a speculative near-term buy ahead of Nov 3 earnings supported by FDA label expansion, upcoming European/Japanese launches, strong margins, and positive biotech sector trends, with cautious risk management due to seasonal sales softness and inventory build.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Very high margins ⢠Extremely liquid ⢠Rich valuation KRYS exhibits exceptional profitability and liquidity (net margin 53%, gross 94%, ROE ~19%, ROIC ~26%, current ratio ~9.95, cash >> debt) but is priced richly versus earnings and cash flow (P/E ~41, EV/EBITDA ~40).
Price Behavior
Key Price Behavior Insights: ⢠Short-term downtrend ⢠Repeated resistance ⢠Mid-$240s support Support Level: $244â$249 (mid-$240s; lows $233.37â$244.71) Resistance Level: $270â$277 (near-month SMA ~$270.80); decisive >$277â$288 to regain bullish trend Price is in a short-term downtrendâdown ~12% over the last month from $287.84 to $253.69, trading below the last-month SMA near $270.80 with resistance at $270â$277â$288 and support in the mid-$240s.
Sentiment & News
Key News Insights: ⢠High VYJUVEK sales ⢠Regulatory wins ⢠Institutional interest Krystal Biotech posted strong VYJUVEK sales and cash, growing reimbursements and pipeline regulatory wins (RMAT/Fast Track) that, along with institutional buying and analyst upgrades, drove a positive market reaction.
AI Summary
Krystal's evolution from a binary clinical play to a highâmargin, cashâgenerating commercial rareâdisease company means valuation should be driven by durable VYJUVEK economics and successful international launches rather than single trial outcomes; investors should therefore prioritize monitorable commercial KPIs (gross margins, receivables/cash conversion, payer coverage) and cash runway. Key immediate risks/opportunities: sustainment of midâ90s gross margins as exâU.S. mix ramps and the next pivotal readouts will be the primary catalysts that could rapidly re-rate the richly priced stock.
Description
Krystal Biotech is a clinical-stage biotechnology company developing redosable gene therapies for serious, primarily rare, dermatologic and genetic conditions. Its lead candidate, beremagene geperpavec (B-VEC), is in Phase III for dystrophic epidermolysis bullosa, while a portfolio of other programs spans early- and preclinical development for congenital ichthyosis, netherton syndrome, cystic fibrosis and multiple dermatology indications including aesthetic applications. The company was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | KRYS | Krystal Biotech, Inc. | Selected as a speculative near-term buy ahead of Nov 3 earnings supported by FDA label expansion, upcoming European/Japanese launches, strong margins, and positive biotech sector trends, with cautious risk management due to seasonal sales softness and inventory build. | Closed | +0.9% |